Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review.
Silvia Boeri, Luca Bosisio, Giulia Prato et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the efficacy and safety of cannabinoid-based products (CBPs) in children and adolescents with Autism Spectrum Disorder, Fragile X Syndrome, and Rett Syndrome. Seventeen studies were included, revealing that CBPs were generally associated with mild-to-moderate adverse events and low discontinuation rates. Notably, behavioral improvements were suggested in Autism Spectrum Disorder and Fragile X Syndrome, while seizure reduction was observed in Rett Syndrome.
Key findings
- CBPs were associated with mild-to-moderate adverse events and low discontinuation rates.
- Behavioral improvements were suggested in Autism Spectrum Disorder and Fragile X Syndrome.
- Seizure reduction was observed in Rett Syndrome.
- Exploratory analyses indicated differential effects of CBD versus CBD + THC on outcomes in Autism Spectrum Disorder.
Why it matters
Understanding the potential benefits and risks of cannabinoid-based products in pediatric neurodevelopmental disorders is crucial for clinicians. This review highlights the need for careful consideration of treatment options and the importance of high-quality evidence in guiding clinical practice.